Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer

NCT00309985 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT00309985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00309985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 3
Overall status
Completed
Start date
September 26, 2006
Completion date
January 31, 2025
Enrollment
790 (actual)
Sites
343

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic hormone-sensitive prostate cancer